A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866 · tracked via the Priya Life Science USA tracker

Sponsor

Target PharmaSolutions, Inc.

Phase

Observational

Started

2018-12-21

Last updated

2026-03-20

Condition(s) studied

Atopic DermatitisAlopecia AreataHidradenitis SuppurativaVitiligoPsoriasisChronic Spontaneous Urticaria

Study summary

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * 1\. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment. * 2\. Participant has plans for future visits at the site for continued management of IMISC. Exclusion Criteria: * 1\. Inability to provide written informed consent/assent. * 2\. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Primary outcome measure(s)

Characterize IMISC Treatment Regimens in Clinical Practice — 25 Years
Enable characterization of IMISC disease activity and comorbid medical conditions over time.
Evaluate Patient Outcomes in Clinical Practice — 25 Years
Enable characterization of IMISC disease activity and comorbid medical conditions over time.
Evaluate Adverse Events of IMISC and treatment in Clinical Practice — 25 Years
Enable characterization of IMISC disease activity and comorbid medical conditions over time.

Trial sites (62)

Facility	City	Region
Clear Dermatology & Aesthetics Center/Investigative MD	Scottsdale	Arizona
Johnson Dermatology	Fort Smith	Arkansas
University of Arkansas for Medical Sciences	Little Rock	Arkansas
Arkansas Dermatology	Little Rock	Arkansas
First OC Dermatology	Fountain Valley	California
Center for Dermatology Cosmetic and Laser Surgery	Fremont	California
University of California	Irvine	California
University of California - San Diego/Rady Children's Hospital	San Diego	California
George Washington University	Washington D.C.	District of Columbia
Feinstein Dermatology and Cosmetic Surgery	Hollywood	Florida
Academic Alliance in Dermatology	Tampa	Florida
Integrated Dermatology of West Palm Beach	West Palm Beach	Florida
Lurie Children's Hospital/Northwestern University	Chicago	Illinois
Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group	Indianapolis	Indiana
The University of Kansas Medical Center	Kansas City	Kansas
Family Allergy and Asthma Research Institute	Louisville	Kentucky
DermAssociates, LCC	Rockville	Maryland
Integrated Dermatology of Massachusetts	Quincy	Massachusetts
University of Massachusetts Medical School	Worcester	Massachusetts
University of Minnesota	Minneapolis	Minnesota
Mayo Clinic	Rochester	Minnesota
Carl Thornblade, MD, PLLC	Missoula	Montana
South Lincoln Dermatology Clinic	Lincoln	Nebraska
Advanced Dermatology of the Midlands	Omaha	Nebraska
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire
Windsor Dermatology	East Windsor	New Jersey
Linda Susan Marcus	Wyckoff	New Jersey
Centurion Dermatology	Brooklyn	New York
The University of Buffalo	Buffalo	New York
Empire Dermatology	East Syracuse	New York
Forest Hills Dermatology Group	Forest Hills	New York
Greenwich Village Dermatology	New York	New York
Ichan School of Medicine	New York	New York
Advanced Allergy & Asthma, PLLC	Rockville Centre	New York
Montefiore Medical Center	The Bronx	New York
Allergy Partners of Western North Carolina	Asheville	North Carolina
UNC Dermatology	Chapel Hill	North Carolina
Wake Forest University Health Sciences	Winston-Salem	North Carolina
Ohio State University	Columbus	Ohio
Allergy, Asthma & Clinical Research Center	Oklahoma City	Oklahoma

+ 22 more sites — see the full list on the official registry below.

More Target PharmaSolutions, Inc. trials in the USA

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease Active, not recruiting

An Observational Study of Patients With Chronic Gastrointestinal Disease Active, not recruiting

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC Active, not recruiting

An Observational Study of Patients With Dermatologic Disease Starting soon

An Observational Study of Patients With Chronic Liver Disease Enrolling by invitation

Other trials for the same condition

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa Recruiting

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Active, not recruiting

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) Recruiting

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Recruiting

Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03661866 on ClinicalTrials.gov ↗ ← All trials in the USA